The online version of this article (doi:10.1186/1749-8090-9-81) contains supplementary material, which is available to authorized users.
Nelly Frossard and Reza Tavakoli contributed equally to this work.
The authors declare that they have no competing interests.
Conceived and designed the experiments: RT, AD, AB. Performed the experiments: RT, AD. Analyzed and discussed the data: RT, NF, CL, BS, MG. Contributed reagents/materials/analysis tools: GZ, XM. Wrote the paper: RT, NF. All authors read and approved the final manuscript.
Left ventricular hypertrophy (LVH) is a potent risk factor for sudden death and congestive heart failure.
We tested the effect of sorafenib, a multikinase inhibitor (10 mg/kg, given orally, starting 2 days prior to banding, till sacrifice on day 14), on the development of LVH following aortic banding in rats.
The latter resulted in significant LVH caused by both an increase in cardiomyocyte volume and interstitial collagen deposition. The observed LVH was entirely blocked by sorafenib downregulating both of these components. LVH was associated with PDGF-BB and TGFβ1 overexpression, as well as phosphorylation of c-raf and ERK1/2. Additionally, the transcription factors c-myc and c-fos leading to proliferation as well as the hypertrophy-inducing transcription factor GATA4 and its regulated gene ANP were all upregulated in response to aortic banding. All these overexpressions and upregulations were inhibited upon sorafenib treatment.
We show that sorafenib exhibits a regulatory role on the occurrence of LVH following AB in rats by blocking the rise in growth factors PDGF-BB and TGFβ1, activation of the corresponding c-Raf-ERK1/2 signaling pathway and effector mechanisms, including GATA4 and ANP. This effect of sorafenib may be of clinical importance in modulating the maladaptive hypertrophic response to pressure overload.
Authors’ original file for figure 113019_2013_1457_MOESM1_ESM.tiff
Authors’ original file for figure 213019_2013_1457_MOESM2_ESM.tiff
Authors’ original file for figure 313019_2013_1457_MOESM3_ESM.tiff
Authors’ original file for figure 413019_2013_1457_MOESM4_ESM.tiff
Authors’ original file for figure 513019_2013_1457_MOESM5_ESM.tiff
Authors’ original file for figure 613019_2013_1457_MOESM6_ESM.tiff
Authors’ original file for figure 713019_2013_1457_MOESM7_ESM.tiff
Muslin AJ: MAPK signaling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin Sci (Lond). 2008, 115: 203-218. 10.1042/CS20070430. CrossRef
Koitabashi N, Danner T, Zaiman AL, Pinto YM, Rowell J, Mankowski J, Zhang D, Nakamura T, Takimoto E, Kass DA: Pivotal role of cardiomyocyte TGF-beta signaling in the murine pathological response to sustained pressure overload. J Clin Invest. 2011, 121: 2301-2312. 10.1172/JCI44824. CrossRefPubMedPubMedCentral
Kobayashi N, Nakano S, Mori Y, Mita S, Kobayahi T, Honda T, Tsubokou Y, Matsuoka H: Betaxolol inhibits extracellular signal-regulated kinase and P70S6 kinase activities and gene expressions of platelet-derived growth factor A-chain and transforming growth factor-beta1 in Dahl salt-sensitive hypertensive rats. Hypertens Res. 2002, 25: 211-219. 10.1291/hypres.25.211. CrossRefPubMed
Bisping E, Ikeda S, Kong SW, Tarnavski O, Bodyak N, McMullen JR, Rajagopal S, Son JK, Ma Q, Springer Z, Kang PM, Izumo S, Pu WT: Gata4 is required for maintenance of postnatal cardiac function and protection from pressure overload-induced heart failure. Proc Natl Acad Sci. 2006, 103: 14471-14476. 10.1073/pnas.0602543103. CrossRefPubMedPubMedCentral
Del Re DP, Sadoshima J: Is Raf1 a nexus for cardiac hypertrophic signaling in human disease?. J Moll Cell Cardiol. 2011, 55: 1-3. CrossRef
Klein M, Schermuly RT, Ellinghaus P, Milting H, Riedl B, Nikolova S, Pullamsetti SS, Weissmann N, Dony E, Savai R, Ghofrani HA, Grimminger F, Busch AE, Schäfer S: Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation. 2008, 118: 2081-2090. 10.1161/CIRCULATIONAHA.108.779751. CrossRefPubMed
Moreno-Vinasco L, Gomberg-Maitland M, Maitland ML, Desai AA, Singleton PA, Sammani S, Sam L, Liu Y, Husain AN, Lang RM, Ratain MJ, Lussier YA, Garcia JGN: Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol Genomics. 2008, 33: 278-291. 10.1152/physiolgenomics.00169.2007. CrossRefPubMedPubMedCentral
Allard MF, Schönekess BO, Henning SL, English DR, Lopaschuk GD: Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am J Physiol. 1994, 267 (2 Pt 2): H742-H750. PubMed
Li Y, Saito Y, Kuwahara K, Rong X, Kishimoto I, Harada M, Adachi Y, Nakanishi M, Kinoshita H, Horiuchi M, Murray M, Nakao K: Guanylyl cyclase-A inhibits angiotensin II type 2 receptor-mediated pro-hypertrophic signaling in the heart. Endocrinology. 2009, 150: 3759-3765. 10.1210/en.2008-1353. CrossRefPubMed
Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Pot LE, Bollag G, Trail P: BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64: 7099-7109. 10.1158/0008-5472.CAN-04-1443. CrossRefPubMed
Liu J, Bai H, Xing DQ, Sun YP, Wu LL: Role of platelet-derived growth factor receptor-mediated signal transduction in myocardial hypertrophy of spontaneously hypertensive rats. Sheng Li Xue Bao. 2002, 54: 159-164. PubMed
- Multikinase inhibitor sorafenib prevents pressure overload-induced left ventricular hypertrophy in rats by blocking the c-Raf/ERK1/2 signaling pathway
- BioMed Central
Neu im Fachgebiet Chirurgie
Mail Icon II